Inhaled corticosteroids (ICSs) have potent anti-inflammatory and immunosuppressant properties. Their use in treating asthma and some forms of COPD patients is well established; however, there is little evidence for their use in bronchiectasis.

More than 50% of patients with bronchiectasis not due to asthma, COPD, or eosinophilic diseases take ICSs, although the current international guidelines on bronchiectasis discourage this practice.

Due to the paucity of information on the effect of ICSs in bronchiectasis without COPD or asthma, no definitive conclusions can be drawn either for or against the use of ICSs in bronchiectasis.